Compare the evidence

Sources, findings and their limits
Source and designPopulation or scopeFindingLimits
Official Atopica and Cyclavance labels [1] [2]Dog and cat oral solutionsKetoconazole can increase ciclosporin concentrations; P-glycoprotein interactions are a separate concern.Atopica cat studies with selamectin or milbemycin did not appear associated with neurotoxicity; this does not cover every parasite product.
Archer et al., 2014 — narrative review [3]Oral ciclosporin in dogsFormulation, whole-blood sampling, assay and timing affect exposure interpretation.No universal concentration target across species or indications.
Mealey et al., 2023 — narrative review [4]Canine and feline P-glycoproteinInherited deficiency and acquired drug-related dysfunction can affect drug distribution.Mechanistic context, not a risk percentage for a specific parasite-control regimen.

Does this page cover ciclosporin or cyclosporine?

Ciclosporin and cyclosporine are alternative spellings of the ingredient. The reviewed Atopica and Cyclavance sources concern veterinary oral solutions; matching the ingredient name does not establish identical formulations, authorizations or instructions. [1] [2]

Can ketoconazole increase ciclosporin levels?

Yes. Both labels describe a clinically relevant increase in ciclosporin blood concentrations with azoles such as ketoconazole in dogs and cats. The concern is increased exposure; the size of the change depends on the patient and regimen. [1] [2]

Why should parasite medicines be included in a ciclosporin medication review?

Cyclavance identifies ciclosporin as a substrate and inhibitor of MDR1 P-glycoprotein. It warns that reduced blood-brain-barrier efflux of macrocyclic lactones, including ivermectin and milbemycin, could cause central nervous system toxicity. [2]

Does the cat evidence say every macrocyclic-lactone combination causes neurotoxicity?

No. Atopica reports that cat studies with concurrent selamectin or milbemycin did not appear to associate treatment with neurotoxicity. This qualified finding accompanies the transporter warning; it does not establish safety for ivermectin, every formulation or dogs. [1]

Is the interaction evidence enough to adjust ciclosporin at home?

No. The labels place potential adjustments under veterinary supervision. The exact product, treatment indication, other medicines and clinical response are needed before selecting any dose, interval or monitoring approach. [1] [2]

What does this overview leave unresolved?

The labels do not quantify harm for every combination or cover every medicine and species. Other precautions, including vaccination considerations, still apply. Dog-and-cat findings cannot be treated as direct evidence in rabbits, birds or reptiles. [1] [2]

Evidence appraisal

Two pharmacokinetic processes need to be kept separate. Metabolic inhibition can increase systemic ciclosporin exposure, whereas altered P-glycoprotein transport can change where a substrate drug distributes, including access to the central nervous system. A higher blood concentration and impaired protection at the blood-brain barrier are therefore different endpoints. The 2023 review by Mealey and colleagues describes both inherited ABCB1-related deficiency and acquired transporter dysfunction from concurrent medicines. It is a mechanistic review, not a risk estimate for every parasite-control regimen. [1] [2] [4]

Archer and colleagues distinguish oil-based and microemulsified oral ciclosporin preparations and describe variable bioavailability in dogs. That distinction matters when comparing papers or medication histories: identical ingredient names do not guarantee identical exposure. The review also explains that whole-blood concentrations, sampling time and analytical method affect interpretation of therapeutic drug monitoring. Its canine monitoring discussion should not be converted into a universal concentration target for cats or every treatment indication. [3]

Clinical interpretation and follow-up

Formulation and indication determine what an exposure result can mean. If therapeutic drug monitoring is selected, record administration time, sampling time, specimen type and assay with the clinical response. The canine review explains why these variables affect interpretation; it does not require routine monitoring for every patient. [3] [1]

The reassuring Atopica observations concern specific cat use with selamectin or milbemycin, not interchangeable P-glycoprotein substrates. Genetic susceptibility is a separate consideration: the transporter review describes acquired dysfunction as well as inherited ABCB1 deficiency, so a normal genetic result does not exclude an acquired interaction. [1] [4]

Questions for veterinary review

Editorial discussion checklist for your veterinarian:

  • Record the exact ciclosporin product and all parasite-control products, including their ingredients and routes.
  • Distinguish a higher-exposure warning from a clinical observation that did not show an association in a particular cat study.
  • Ask the prescribing veterinarian to assess the complete regimen before changing doses or intervals.

Catalogue review status and evidence limits

The catalogue records contain verified direct evidence (cat, dog): a species-scoped official-label statement, not necessarily a controlled interaction trial. The linked label PDF was also checked for publication.

A verified warning does not establish an individual animal's outcome, a patient-specific dose or independent clinical review. No matching rule does not prove safety.

Evidence sources

Citation scope: official labels support the interaction warnings; research and guidelines provide separately identified context. Each citation shows its document version or literature type and review scope. Catalogue identifiers may refer to earlier versions; this article uses the linked label PDF. Repeated labels are not independent studies. Source URLs and product authorizations may change.

  1. VMD: Atopica 100 mg/ml Oral Solution for Cats and Dogs — Summary of Product Characteristics

    Evidence type: Official product label. Revised September 2025. 4.8, interactions. Page 5. Source checked: . Open official VMD source

  2. VMD: Cyclavance 100 mg/ml Oral Solution for Dogs and Cats — Summary of Product Characteristics

    Evidence type: Official product label. Revised April 2024. 4.8, interactions. Page 4, Page 5. Source checked: . Open official VMD source

  3. Oral cyclosporine treatment in dogs: a review of the literature.

    Archer TM et al. J Vet Intern Med. 2014;28(1):1-20. Evidence type: Narrative review. Review scope: Full text. Source checked: . Open research source

  4. Canine and feline P-glycoprotein deficiency: What we know and where we need to go.

    Mealey KL et al. J Vet Pharmacol Ther. 2023;46(1):1-16. Evidence type: Narrative review. Review scope: Full text. Source checked: . Open research source

Content responsibility: ZooDDI. For veterinary discussion, not diagnosis, prescribing or emergency care. No independent veterinary clinical review has been completed.

Check a complete medication regimen